Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab.
about
Quantification of HER family receptors in breast cancerCorrelation of HER2, p95HER2 and HER3 expression and treatment outcome of lapatinib plus capecitabine in her2-positive metastatic breast cancerHER2 and breast cancer stem cells: more than meets the eye.Quantitative measurement of HER2 expression in breast cancers: comparison with 'real-world' routine HER2 testing in a multicenter Collaborative Biomarker Study and correlation with overall survival.HER2: biology, detection, and clinical implicationsCorrelation between quantitative HER-2 protein expression and risk for brain metastases in HER-2+ advanced breast cancer patients receiving trastuzumab-containing therapyA phase II study of ixabepilone and trastuzumab for metastatic HER2-positive breast cancer.HER3, p95HER2, and HER2 protein expression levels define multiple subtypes of HER2-positive metastatic breast cancer.HER-2 gene amplification in human breast cancer without concurrent HER-2 over-expression.HER2 amplification level is not a prognostic factor for HER2-positive breast cancer with trastuzumab-based adjuvant treatment: a systematic review and meta-analysis.Biomarkers of drugs targeting HER-family signalling in cancer.HER2 testing and its predictive utility in anti-HER2 breast cancer therapy.Identification of prognostic different subgroups in triple negative breast cancer by Her2-neu protein expression.HER2/CEP17 ratio and HER2 immunohistochemistry predict clinical outcome after first-line trastuzumab plus taxane chemotherapy in patients with HER2 fluorescence in situ hybridization-positive metastatic breast cancer.Role of HER2-Related Biomarkers (HER2, p95HER2, HER3, PTEN, and PIK3CA) in the Efficacy of Lapatinib plus Capecitabine in HER2-Positive Advanced Breast Cancer Refractory to Trastuzumab.Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab.Quantitative assessment of HER2 amplification in HER2-positive breast cancer: its association with clinical outcomes.Her2-neu score as a prognostic factor for outcome in patients with triple-negative breast cancer.High-level ERBB2 gene amplification is associated with a particularly short time-to-metastasis, but results in a high rate of complete response once trastuzumab-based therapy is offered in the metastatic setting.
P2860
Q27015506-13197072-AAEE-4232-9983-F3F3D9CC90ABQ28728701-83A2373A-CF5A-439B-87CB-1AB2956922DDQ35320325-7DB4CE78-EEC5-425A-8201-B865F53D669CQ35343184-54D48337-A288-431D-BF08-6CB56FC0C1B9Q35622862-87651423-17AD-4CBD-8E33-20175F3DAEBFQ35705221-3886C6B7-C05D-48AE-B862-DACC94A78467Q36950497-CACC0EFB-6B6E-4425-AD72-A6D09211579AQ37136419-2A08DF56-1C47-4A97-BC4D-D4A81D5D1194Q37216946-1B6CF8D8-E2FD-483A-9EC1-C9E378C82CC7Q37665397-032C8019-C81C-4389-8A33-8E9D073331E3Q38150774-9E010F1E-F764-470F-8C5E-8338F32FFFE1Q38326102-BD8E47EE-8D2A-430D-9BF1-D47D2B5DED09Q50658602-9C994E69-1813-43F4-85CE-AA95BF6AEDFCQ50994494-3631E513-15C6-4EAF-BF30-A7B7614755EAQ51016839-4A44EC2B-59A7-4E8B-BE65-09CDD42DEDC1Q53507006-C345B0C3-7FB7-4BA6-93D0-90E969F005C6Q53581875-F493075E-D24E-46CC-A165-BBA7C0396CB7Q54110141-5CAC1CE4-5CD1-4EFE-BA50-03CE2C8CA658Q54392190-DC6FCE5C-1738-4228-9D8C-83785A035E3B
P2860
Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Quantitative HER2 protein leve ...... ncer treated with trastuzumab.
@en
Quantitative HER2 protein leve ...... ncer treated with trastuzumab.
@nl
type
label
Quantitative HER2 protein leve ...... ncer treated with trastuzumab.
@en
Quantitative HER2 protein leve ...... ncer treated with trastuzumab.
@nl
prefLabel
Quantitative HER2 protein leve ...... ncer treated with trastuzumab.
@en
Quantitative HER2 protein leve ...... ncer treated with trastuzumab.
@nl
P2093
P2860
P356
P1433
P1476
Quantitative HER2 protein leve ...... ncer treated with trastuzumab.
@en
P2093
Agnes Paquet
Allan Lipton
Jeff Sperinde
Jodi Weidler
Kim Leitzel
Michael Bates
Suhail M Ali
Thomas Sherwood
Trastuzumab Response Biomarker Group
Weidong Huang
P2860
P304
P356
10.1002/CNCR.25430
P407
P577
2010-11-01T00:00:00Z